Key stats
About Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF Accum-1C- USD
Home page
Inception date
Jul 12, 2022
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
DWS Investment SA
ISIN
IE000KD0BZ68
Functions as an open-end investment fund
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.89%
Health Technology86.76%
Health Services9.46%
Commercial Services3.29%
Electronic Technology0.22%
Finance0.16%
Bonds, Cash & Other0.11%
Cash0.11%
Stock breakdown by region
North America71.15%
Europe22.25%
Asia6.26%
Oceania0.34%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
XGEN invests in stocks. The fund's major sectors are Health Technology, with 86.76% stocks, and Health Services, with 9.46% of the basket. The assets are mostly located in the North America region.
XGEN top holdings are Agilent Technologies, Inc. and Natera, Inc., occupying 5.04% and 4.93% of the portfolio correspondingly.
No, XGEN doesn't pay dividends to its holders.
XGEN shares are issued by Deutsche Bank AG under the brand Xtrackers. The ETF was launched on Jul 12, 2022, and its management style is Passive.
XGEN expense ratio is 0.35% meaning you'd have to pay 0.35% of your investment to help manage the fund.
XGEN follows the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
XGEN invests in stocks.